Germany
Investigative Toxicologist, experience in Pharma (16y) and Agrochemical Industry (5y) as well as Academia. People leader. Safety Representative for discovery projects. Mode of Action (MOAs) study, Hypothesis driven, Target Safety Assessment, and Safety/Derisking Strategies. Highly specialised in molecular toxicology, NAMs, NGRA, 3Rs, Molecular Initiating Events (MIEs),
- Team leader (8 direct reports) in a matrix organisation. - Early Tox representative for PROTACs (Oerthbio collaboration) - Short term assignment 04.2023-03.2024: Early tox representative for Disease Control - Short term assignment 04.2024-11.2025: New Approach Methodologies for Next Generation Risk Assessment focus team
ITLF is an open, non-exclusive forum of European-based Investigative Toxicology leaders from the pharmaceutical industry aiming to enhance the interaction with experts form academia and regulatory bodies in the field of investigative toxicology. * to jointly elaborate robust, reliable and accepted I-Tox concepts for decision making for early safety-related attrition, de-risking, and mechanistic elucidation of safety-related effects, * to increase the understanding and improve the translation of in vitro to in vivo mechanistic data. Furthermore, the adoption of new technologies/platforms into the drug discovery back-bone is targeted by the forum, * to increase the knowledge and awareness on Investigative Toxicology as a discipline (e.g., through publications, meetings and conferences).
Safety representative in early projects (target identification/ hit to lead/ candidate selection) Target safety assessment Discovery Safety Validation and implementation of novel in vitro approaches to predict in vivo toxicity Special interest in molecular toxicity mechanisms and mitochondrial toxicity in particular
Secretary of the BCLAS (FELASA). Co-organizer and chair of several events in the frame of the 3Rs